FHTX
Foghorn Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 21 ▲ Foghorn Therapeutics presented new preclinical data at AACR 2026 sho…
- Apr 21 FDA: Foghorn Therapeutics Presents New Preclinical Data for Sel…
- Oct 1 ▼ Foghorn Therapeutics is discontinuing its Phase 1 trial of FHD-909 (…
- Oct 1 Trading halt: Trading Halt: FHTX, T1 (News Pending)
- Oct 1 Trading halt: Halt Resumed: FHTX, trading resumed after T3 (News and Res…
- Oct 1 Trading halt: Trading Halt: FHTX, T3 (News and Resumption Times)
- Oct 2 ▼ 3 downgrades
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 17 added (0 new), 6 trimmed or exited.
- AnalystsBULLISH
10 of 16 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −8.3% to 2.25M shares. 3.9 days to cover, ≈3.8% of shares.
- TrendRANGE
34% below its 50-day average. New closing low $1.79 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | DOUBLED | $2.3M |
| Qube Research & Technologies Ltd | DOUBLED | $1.9M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $810.7K |
| MORGAN STANLEY | ADD | $617.0K |
| UBS Group AG | DOUBLED | $448.1K |
| BARCLAYS PLC | ADD | $102.7K |
| SIMPLEX TRADING, LLC | DOUBLED | $56.3K |
| STRS OHIO | ADD | $41.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +179%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 2, 2026 | Wedbush DOWNGRADE | Neutral |
| Oct 2, 2026 | TD Cowen DOWNGRADE | Hold |
| Oct 2, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 2, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 2, 2026 | BTIG DOWNGRADE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
PARSHALL B LYNNE Director Jun 24, 2026 | AWARD | $114.2K |
GILL SIMBA Director Jun 24, 2026 | AWARD | $114.2K |
SMITH IAN F Director Jun 24, 2026 | AWARD | $114.2K |
Cole Douglas G. Director Jun 24, 2026 | AWARD | $114.2K |
Biller Scott Director Jun 24, 2026 | AWARD | $114.2K |
Mendelsohn Michael Director Jun 24, 2026 | AWARD | $114.2K |
Gallagher Neil Director Jun 24, 2026 | AWARD | $114.2K |
Lynch Thomas J. Jr. Director Jun 24, 2026 | AWARD | $114.2K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.23 | -$0.26–-$0.18 | +4.2% | $4.2M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Oct 1, 2026 | Resumption Scheduled | Resumed |
SecBot reports
8 filings · 1 press release · 1 bullish · 1 bearish · 1 mixed · 5 neutral- NEUTRAL INST-CLUSTERNov 16, 2026
In Q2 2026, 15 institutions accumulated $792K in FHTX while 4 reduced holdings by $526K, a net bullish cluster. The buying follows a Q3 earnings beat with $58.2M net income and $156M cash runway, though the 13F data is 45+ days stale and the stock's market cap is only $123M.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 9, 2026
Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up…
The reported profit is entirely from a non-recurring catch-up adjustment; the underlying operating loss (ex-catch-up) was approximately $15.9M. Monitor the 10-Q for details on the restructuring and…
- NEUTRAL 3Oct 5, 2026
BVF entities (Biotechnology Value Fund, BVF Partners, and affiliates) filed a Form 3 initial…
Monitor for any subsequent Schedule 13D amendments or open-market transactions by BVF entities, which would signal a change in investment thesis. The pre-funded warrants at $0.0001 and Series 1/2…
- NEUTRAL SC 13G/AOct 5, 2026
Biotechnology Value Fund L.P. (BVF) and affiliated entities filed an amended Schedule 13G on…
BVF's passive 13G filing confirms a large, stable position with no activist intent. The fully blocked warrants suggest the fund is capped at current ownership levels unless it seeks to exceed 9.99%…
All FHTX filing & press-release reports (9)
- INST-CLUSTER reportNov 16, 2026
- PRESS-RELEASE reportNov 9, 2026
- 3 reportOct 5, 2026
- SC 13G/A reportOct 5, 2026
- 8-K reportOct 1, 2026
- 8-K reportAug 6, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026